CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2016 AACR Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Sandra Demaria on Radiation and Immunotherapy Combination Regimens
Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma
Dr. Barbieri on SPOP Mutations in Prostate Cancer
Oncology Conference Articles
Entinostat/IL-2 Combination Active in Previously Untreated Renal Cell Carcinoma
More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.
Using Multiple Biomarkers Improves Risk Prediction for Breast Cancer
The addition of three biological markers to conventional breast cancer risk models significantly improved the ability to distinguish women at high and low risk.
Frontline Pembrolizumab Induces Durable Responses in Merkel Cell Carcinoma
Antiâ€“PD-1 therapy in the first-line induced responses in more than half of patients with advanced Merkel cell carcinoma, with encouraging durability to the responses.
Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer
Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.
PD-L1 Expression Assays Show Similar Performance for NSCLC
Three currently available assays for PD-L1 expression exhibited a high degree of correlation in a comparative study involving archived lung cancer tissue.
Neoadjuvant T-DM1 Plus Pertuzumab Shows Promise for HER2-Positive Breast Cancer
The combination of ado-trastuzumab emtansine and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer.
PARP/AKT Inhibitor Combination Active in Multiple Tumor Types
The combination of the PARP inhibitor olaparib and the investigational AKT inhibitor AZD5363 resulted in durable responses in patients with solid tumors, with and without BRCA mutations.
Two Genetic Variants May Signal Which Survivors Are at Highest Risk for Breast Cancer After Chest Radiation
Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood
Palbociclib Showed Antiproliferative Activity in Early-stage Breast Cancer
Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.
70-Gene Signature Identifies Breast Cancer Subgroup Unlikely to Benefit From Adjuvant Chemo
A 70-gene signature (MammaPrint) demonstrated a high level of accuracy at identifying a large subset of women with clinically high-risk early stage breast cancer for whom adjuvant chemotherapy was unlikely to produce benefit.
Nivolumab/Ipilimumab Combination Shows Survival Benefit in Advanced Melanoma
The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) showed a 42% improvement in overall survival compared with ipilimumab monotherapy for patients with advanced melanoma in a 2-year assessment of the phase II CheckMate-069 trial.
Entrectinib Achieves High Response Rate Across Solid Tumors
Treatment with the novel multikinase inhibitor entrectinib achieved objective responses in 79% of patients with solid tumors associated with NTRK, ROS-1, or ALK rearrangements.
MAGE-A3—Targeted Adoptive T-Cell Therapy Shows Promise in Solid Tumors
A form of immunotherapy that harnesses the power of CD4 T-cells was shown to be safe and effective in patients with various types of metastatic cancers.
Nivolumab Shows Impressive Long-Term OS in Melanoma
Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma who had not received prior ipilimumab.
FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC
PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects
Sacituzumab Govitecan Active in Advanced Urothelial Carcinoma
Targeting BCL-2 in Hematologic Malignancies
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.